Get started
Author

Eriko Tabata

Observed names: E. Tabata, E., Tabata, Eriko TABATA
Observed institution: Ikeda Municipal Hospital
ORCID: 0000-0002-8919-6139
Observed ORCID: 0000-0002-8919-6139
OpenAlex ID: A5070236738
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2022 · Akira Sugimoto, Shingo Matsumoto, et al. · Clinical Cancer Research · 76
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
2023 · Takeshi Masuda, Satoru Miura, et al. · Scientific Reports · 6
PDF
Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)
2023 · Motoko Tachihara, Akito Hata, et al. · JTO Clinical and Research Reports · 3
Clinical, genomic, and pathological features and therapeutic outcomes of non-small cell lung cancer with MTAP-loss.
2025 · Hibiki Udagawa, Shingo Matsumoto, et al. · Journal of Clinical Oncology · 2
The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.
2022 · Yuki Sato, Takeshi Masuda, et al. · Journal of Clinical Oncology · 2
Prognostic impact of actionable driver alterations and efficacy of targeted therapy in lung squamous cell carcinoma: A large-scale nationwide genomic screening (LC-SCRUM-Asia).
2026 · Tetsuya Sakai, Hiroki Izumi, et al. · Journal of Clinical Oncology · 1
Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al. · 1
Discrepancy between plasma cell-free DNA and tissue-based analysis for detection of gene amplifications in non–small cell lung cancer.
2026 · Haruka Nakatani, Hibiki Udagawa, et al. · Journal of Clinical Oncology
PDF
Supplementary Figures S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2025 · Akira Sugimoto, Shingo Matsumoto, et al.
PDF
Supplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2025 · Akira Sugimoto, Shingo Matsumoto, et al.
P2.02-03 Association of irAEs with the Efficacy of PACIFIC Regimen in Patients with Unresectable Stage III NSCLC: WJOG11518L/SUBMARINE
2023 · Y. Toi, K. Haratani, et al. · Journal of Thoracic Oncology
PDF
Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
Supplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
Supplementary Figures S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
PDF
Supplementary Figure from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
PDF
Supplementary Figure from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
Supplementary Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
Supplementary Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al.
MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia
2022 · Yosuke Kagawa, Kaname Nosaki, et al. · Annals of Oncology
Abstract 5238: CLIP1-LTK: A novel druggable gene fusion in non-small cell lung cancer
2022 · Hiroki Izumi, Shingo Matsumoto, et al. · Cancer Research
Supplementary Material for: Clinical Utility of Surgical Lung Biopsy for Patients with Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis
2021 · H., Hashimoto, S., Yamamoto, et al. · Figshare
Immuno-oncology biomarker study in a large cohort of LC-SCRUM-Japan: LC-SCRUM-IBIS
2018 · Kei Kunimasa, Kiyotaka Yoh, et al. · Annals of Oncology
P1.01-34 Docetaxel Plus Ramucirumab with Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L)
2018 · A. Hata, N. Katakami, et al. · Journal of Thoracic Oncology
A Case of Successfully Treated Acute Respiratory Distress Syndrome Complicated by Ureteral Stones
2008 · Naoki CHIKUIE, Kazuhiko FUJITA, et al. · Kansenshogaku zasshi
PDF
Works count: 24
Citation count: 91
H-index: 3
I10-index: 1
Year
Topic
Type